1. Home
  2. DARE vs SPHL Comparison

DARE vs SPHL Comparison

Compare DARE & SPHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DARE
  • SPHL
  • Stock Information
  • Founded
  • DARE N/A
  • SPHL 2002
  • Country
  • DARE United States
  • SPHL Singapore
  • Employees
  • DARE N/A
  • SPHL N/A
  • Industry
  • DARE Biotechnology: Pharmaceutical Preparations
  • SPHL Homebuilding
  • Sector
  • DARE Health Care
  • SPHL Consumer Discretionary
  • Exchange
  • DARE Nasdaq
  • SPHL Nasdaq
  • Market Cap
  • DARE 27.9M
  • SPHL 27.5M
  • IPO Year
  • DARE N/A
  • SPHL 2024
  • Fundamental
  • Price
  • DARE $3.17
  • SPHL $2.60
  • Analyst Decision
  • DARE Strong Buy
  • SPHL
  • Analyst Count
  • DARE 4
  • SPHL 0
  • Target Price
  • DARE $20.33
  • SPHL N/A
  • AVG Volume (30 Days)
  • DARE 25.7K
  • SPHL 416.7K
  • Earning Date
  • DARE 03-27-2025
  • SPHL 02-21-2025
  • Dividend Yield
  • DARE N/A
  • SPHL N/A
  • EPS Growth
  • DARE N/A
  • SPHL 413.11
  • EPS
  • DARE N/A
  • SPHL 0.09
  • Revenue
  • DARE $1,881,316.00
  • SPHL $11,020,429.00
  • Revenue This Year
  • DARE N/A
  • SPHL N/A
  • Revenue Next Year
  • DARE $136.52
  • SPHL N/A
  • P/E Ratio
  • DARE N/A
  • SPHL $29.72
  • Revenue Growth
  • DARE 88.13
  • SPHL 112.84
  • 52 Week Low
  • DARE $2.67
  • SPHL $1.42
  • 52 Week High
  • DARE $7.56
  • SPHL $7.16
  • Technical
  • Relative Strength Index (RSI)
  • DARE 50.64
  • SPHL N/A
  • Support Level
  • DARE $2.95
  • SPHL N/A
  • Resistance Level
  • DARE $3.31
  • SPHL N/A
  • Average True Range (ATR)
  • DARE 0.15
  • SPHL 0.00
  • MACD
  • DARE 0.01
  • SPHL 0.00
  • Stochastic Oscillator
  • DARE 61.11
  • SPHL 0.00

About DARE Dare Bioscience Inc.

Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation.

Share on Social Networks: